News

CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies

Strategic in-license from Cortice Bioscience is highly synergistic with the ongoing potentially pivotal Berubicin program and demonstrates further commitment to…

1 year ago

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August

NORWOOD, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced…

1 year ago

Canadian Red Cross announces financial assistance for people evacuated from Jasper due to wildfires in Alberta

$750 will be provided to households evacuated from their primary residence in JasperOTTAWA, July 30, 2024 (GLOBE NEWSWIRE) -- The…

1 year ago

Canadian Red Cross announces financial assistance for people evacuated from Jasper due to wildfires in Alberta

$750 will be provided to households evacuated from their primary residence in JasperOTTAWA, July 30, 2024 (GLOBE NEWSWIRE) -- The…

1 year ago

Zevra Therapeutics to Report Second Quarter 2024 Financial Results

Audio Webcast schedule to be held on August 13, 2024 at 4:30 p.m. ETCELEBRATION, Fla., July 30, 2024 (GLOBE NEWSWIRE)…

1 year ago

Evoke Pharma, Inc. Announces Reverse Stock Split

SOLANA BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily…

1 year ago

Milestone Scientific Secures Key Patent Approvals in the U.S. and Europe

ROSELAND, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery…

1 year ago

Neuronetics Announces the Closing of up to $90 Million Senior Secured Credit Facility with Perceptive Advisors

MALVERN, Pa., July 30, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing,…

1 year ago

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference

Preclinical data showed strong antibody responses with no measurable pro-inflammatory T cell responses against AßO and support novel approach for…

1 year ago

Cassava Sciences Announces Expansion of Open-Label Extension Trials

Ongoing open-label extension trials of simufilam in Alzheimer’s disease to be extended by up to an additional 36 months. The…

1 year ago